Premium
Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma
Author(s) -
Smith Malcolm A.,
Kang Min H.,
Reynolds C. Patrick,
Kurmasheva Raushan T.,
Alexander Denise,
Billups Catherine A.,
Toretsky Jeffrey A.,
Houghton Peter J.
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23391
Subject(s) - arsenic trioxide , medicine , sarcoma , arsenic , in vivo , ewing's sarcoma , cancer research , pharmacology , oncology , pathology , biology , chemistry , microbiology and biotechnology , organic chemistry
Arsenic trioxide was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5 mg/kg daily × 5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC 50 value of 0.9 µM, with Ewing sarcoma cell lines having IC 50 values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed. Pediatr Blood Cancer 2012;59:753–755. © 2012 Wiley Periodicals, Inc.